Evidence Explorer / Evidence record

MS-N014 · Literature searched October 13, 2026 · Appraised October 13, 2026 · Hot flashes / sleep

Evidence at a glance

• Breast-cancer trial: 60 survivors with at least 14 hot flashes per week were randomized to five weekly hypnosis sessions or no treatment; 51 completed the study.
• Result: hot-flash score fell 68% from baseline in the hypnosis arm, with better sleep and less interference. The no-treatment comparator could not control for attention or expectation.
• Tougher comparison: a 2025 trial randomized 250 women to daily 20-minute self-hypnosis recordings or a white-noise sham for six weeks; 62 had a breast-cancer history.
• Overall six-week result: hot-flash score fell 53.4% with hypnosis versus 40.9% with sham; daily-life interference fell 49.3% versus 37.4%.
• Boundary: neither trial tested recurrence, survival or endocrine-therapy efficacy.

What was studied?

The 2008 trial enrolled survivors without detectable disease and used clinician-delivered sessions. The 2025 trial included broader postmenopausal populations and allowed women with stage 0–III breast cancer on stable endocrine therapy or antidepressants. Participants listened daily to recordings using relaxation and cooling imagery. The main outcome combined hot-flash frequency and severity.

In the 2025 breast-cancer subgroup, mean hot-flash score fell from 98.2 to 35.4 at week 6 with hypnosis and from 84.7 to 54.6 with sham; the time-by-group effect was statistically significant. This subgroup included only 62 participants, so the estimate remains imprecise and should not be treated as a stand-alone definitive cancer trial.

What can we conclude?

Clinical hypnosis is a reasonable evidence-supported nonhormonal option for hot-flash symptom control. The sham group also improved substantially, which makes the incremental benefit more informative than a dramatic before-and-after percentage. Follow-up in the newer trial extended only to 12 weeks, and adherence differed over time. A structured protocol should not be generalized automatically to every app, video or generic relaxation recording.

Safety and practical context

No intervention-related adverse events were reported in the 2025 trial. Hypnosis should be practiced in a safe setting, never while driving. People who experience distress, dissociation or worsening psychiatric symptoms should stop and seek guidance. New fever, drenching sweats or changing symptoms still need medical evaluation; do not change endocrine therapy without the oncology team.

Funding and conflicts: The 2025 trial was funded by NCCIH grant 1R01AT009384. One author reported personal fees from Mindset Health outside the work, and another reported institutional Breast Cancer Research Foundation grants. The 2008 trial reported NCI grant support; one investigator disclosed consulting and industry research relationships.

Questions for the care team

• Does the symptom pattern fit hot flashes, or should another cause be checked?
• Can the team recommend a qualified clinician or a recording program based on a studied protocol?
• What improvement in frequency, severity or sleep would count as worthwhile?
• How should this fit alongside nonhormonal medications or endocrine therapy?

Sources

• Elkins et al., 2008 breast-cancer survivor trial — PMID 18809612; DOI 10.1200/JCO.2008.16.6389
• Elkins et al., 2025 sham-controlled trial — DOI 10.1001/jamanetworkopen.2025.42537
• 2023 Menopause Society nonhormone position statement — PMID 37252752

Learn how to judge a study · Return to the evidence map

This evidence brief is educational, not a personal treatment recommendation. Research regimens are not prescribing instructions. Symptom benefit does not establish tumor response, recurrence prevention or survival benefit.